Regeneron : EYLEA HD Three-Year Results Show Lasting Vision Gains In Diabetic Macular Edema Patients
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME).
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1116617012-6a8112931e6f4375b6e1481b39eeeae8.jpg "How to Become a Real Estate Agent: A Step-by-Step Guide")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1255077848-13fe034d27ba4d1398930d76d7be6693.jpg "6 Best Paying Jobs in Finance")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1246195248-4209faa3f1854e648d38836ebd402e96.jpg "Forex Market Sentiment Indicators and How To Use Them")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1144526482-502cd0f081c9408bb9df5e768a5f6efe.jpg "The Stunning Earnings of the Biggest Movie Franchises—See How They Compare")